Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. Haematologica 2007;92:846-9.
Gröner
A
A
D016913:Blood Component Transfusion / Q000009:adverse effects*; D004196:Disease Outbreaks / Q000517:prevention & control; D005169:Factor VIII; D005340:Fibrinogen / Q000009:adverse effects* / Q000302:isolation & purification / Q000592:standards* / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D011338:Probability Theory; D012306:Risk; D013242:Sterilization; D014777:Virus Diseases / Q000635:transmission*; D038301:Virus Inactivation
C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen